Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our s...
Main Authors: | Isabelle Duroux-Richard, Yves-Marie Pers, Sylvie Fabre, Meryem Ammari, Dominique Baeten, Guillaume Cartron, Isabelle Touitou, Christian Jorgensen, Florence Apparailly |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2014/342524 |
Similar Items
-
X-Linked miRNAs Associated with Gender Differences in Rheumatoid Arthritis
by: Olfa Khalifa, et al.
Published: (2016-11-01) -
Safety of rituximab in rheumatoid arthritis
by: F. Atzeni, et al.
Published: (2011-06-01) -
Rituximab for the treatment of rheumatoid arthritis
by: A Bagust, et al.
Published: (2009-09-01) -
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
by: Pers Yves-Marie, et al.
Published: (2011-11-01) -
BIK is a novel pro-apoptotic target gene for miR-125b in human monocytes
by: Fabre S, et al.
Published: (2010-11-01)